+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs



Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs



Journal of the American Veterinary Medical Association 199(8): 1039-1042



Keratoconjunctivitis sicca (KCS) is a prevalent and often vision-threatening condition in dogs. In several reports, 2% cyclosporine (cyclosporin A, CsA) was described as effective in modulating the clinical signs of KCS. This study was designed to compare the efficacy of 1% CsA vs placebo, using a randomized double-blind clinical trial. Topical administration of 1% CsA significantly improved Schirmer wetting values and subjective markers of corneal health as compared with the placebo.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 002050878

Download citation: RISBibTeXText

PMID: 1748606


Related references

Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Biotechnic and Histochemistry 90(3): 223-230, 2015

Keratoconjunctivitis sicca in dogs: Treatment with topical cyclosporine. Veterinary medicine reportng 2(2): 115-127, 1990

Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 199(8): 1043-1046, 1991

Cellular immunity in dogs with keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Veterinary Immunology and Immunopathology 49(3): 199-208, 1995

Topical administration of petrolatum based cyclosporine for treatment of keratoconjunctivitis sicca in dogs. Journal of Veterinary Clinics 19(2): 260-263, 2002

Cellular immunity in dogs with keratoconjunctivitis sicca before and after treatment with topical 2 percent cyclosporine. Veterinary Immunology & Immunopathology 49(3): 199-208, 1995

Microorganisms isolated from the corneal surface before and during topical cyclosporine treatment in dogs with keratoconjunctivitis sicca. American Journal of Veterinary Research 56(7): 880-884, 1995

Conjunctival impression cytology from dogs with keratoconjunctivitis sicca. Pre- and post-treatment with topical cyclosporine. Advances in Experimental Medicine and Biology 438: 997, 1998

Topical cyclosporine therapy for keratoconjunctivitis sicca in dogs. Cornell Veterinarian 79(3): 207-209, 1989

Histologic characteristics and local cellular immunity of the gland of the third eyelid after topical ophthalmic administration of 2% cyclosporine for treatment of dogs with keratoconjunctivitis sicca. American Journal of Veterinary Research 63(5): 688-694, 2002

Topical application of cyclosporine in the management of keratoconjunctivitis sicca in dogs. Journal of the American Animal Hospital Association 26(3): 269-274, 1990

Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial. Veterinary Record 137(20): 504-507, 1995

Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca. Klinische Monatsblatter für Augenheilkunde 229(5): 548-553, 2012

Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Archives of Ophthalmology 107(8): 1210-1216, 1989

Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. Acta Veterinaria Hungarica 64(3): 313-329, 2016